Dr Peter Houweling
Dr Peter Houweling
Details
Role
Team Leader / Senior Research Officer
Research area
Genomic Medicine
Group
Muscle Research
Dr Peter Houweling is a Team leader and senior research officer in the Muscle Research group at the Murdoch Children’s Research Institute (MCRI). He completed his PhD at the University of Sydney and post-doctoral appointments at the Children’s Hospital Westmead, before moving the MCRI in 2013.
He has almost 15 years of experience in the laboratory where he is working to understand the impact of genetic variants on skeletal muscle performance in health and disease.
His Team now focuses on using stem cells to model and test new treatments for patients with genetic muscle diseases, including Duchenne muscular dystrophy (DMD), Facioscapulohumeral muscular dystrophy (FSHD) and other congenital muscular dystrophies.
He has almost 15 years of experience in the laboratory where he is working to understand the impact of genetic variants on skeletal muscle performance in health and disease.
His Team now focuses on using stem cells to model and test new treatments for patients with genetic muscle diseases, including Duchenne muscular dystrophy (DMD), Facioscapulohumeral muscular dystrophy (FSHD) and other congenital muscular dystrophies.
Dr Peter Houweling is a Team leader and senior research officer in the Muscle Research group at the Murdoch Children’s Research Institute (MCRI). He completed his PhD at the University of Sydney and post-doctoral appointments at the Children’s...
Dr Peter Houweling is a Team leader and senior research officer in the Muscle Research group at the Murdoch Children’s Research Institute (MCRI). He completed his PhD at the University of Sydney and post-doctoral appointments at the Children’s Hospital Westmead, before moving the MCRI in 2013.
He has almost 15 years of experience in the laboratory where he is working to understand the impact of genetic variants on skeletal muscle performance in health and disease.
His Team now focuses on using stem cells to model and test new treatments for patients with genetic muscle diseases, including Duchenne muscular dystrophy (DMD), Facioscapulohumeral muscular dystrophy (FSHD) and other congenital muscular dystrophies.
He has almost 15 years of experience in the laboratory where he is working to understand the impact of genetic variants on skeletal muscle performance in health and disease.
His Team now focuses on using stem cells to model and test new treatments for patients with genetic muscle diseases, including Duchenne muscular dystrophy (DMD), Facioscapulohumeral muscular dystrophy (FSHD) and other congenital muscular dystrophies.
Top Publications
- Evesson, FJ, Dziaduch, G, Yasa, J, Best, HA, Kiriaev, L, Pang, I, Jones, V, Kettle, E, Zhang, K, Piper, A-K, et al. Pyroxd1 is essential for murine viability with the homozygous N155S recurrent variant linked to myopathy, muscle hypotrophy and osteopenia.. Acta Neuropathol Commun 2026 view publication
- Kiriaev, L, North, KN, Head, SI, Houweling, PJ. Twisting Paths: The Paradox of Fiber Branching in Muscle Regeneration.. Int J Mol Sci 27(2) : 2026 view publication
- Chung, JD, Trieu, J, Parker, BL, Nguyen, JH, Chee, A, Chan, AS, Jayasimhan, A, Deliyanti, D, Houweling, PJ, Voges, HK, et al. Intrinsic muscle stem cell dysfunction underlies functional deficits in models of type 1 diabetes.. NPJ Regen Med 11(1) : 8 2026 view publication
- Seto, JT, Roeszler, KN, Meehan, LR, Wood, HD, Tiong, C, Bek, L, Lee, SF, Shah, M, Quinlan, KGR, Gregorevic, P, et al. ACTN3 genotype influences skeletal muscle mass regulation and response to dexamethasone. 2026 view publication
- Wyckelsma, V, Venckunas, T, Houweling, P, Schlittler, M, Lauschke, V, Tiong, C, Wood, H, Ivarsson, N, Paulauskas, H, Eimantas, N, et al. Loss of α-actinin-3 during human evolution provides superior cold resilience and muscle heat generation. 2026 view publication
Page 1 of 16
Share //
